MiR-483-5p has the potential to serve as a biomarker in perioperative respiratory adverse events in children under general anesthesia

Perioperative respiratory adverse events (PRAE) may cause critical illness in children undergoing anesthesia and surgery. So, this study aims to explore the diagnostic value of miR-483-5p in PRAE. This study included 112 patients with PRAE and 93 patients without PRAE. MiR-483-5p expression was quantified utilizing RT-qPCR. The receiver operating characteristic (ROC) curve was utilized to assess the diagnostic value. The clinicopathological characteristics of PRAE and miR-483-5p level were analyzed by the Chi-squared test. Risk factors for PRAE were analyzed using multivariate logistic regression. The multicellular human alveolar model was established by treating it with lipopolysaccharide (LPS) at 48 h. Then, cell viability and inflammatory factors were detected in the PRAE model by cell counting kit-8 (CCK-8) assay and ELISA. MiR-483-5p was obviously increased and had high diagnostic value in PRAE. In PRAE, miR-483-5p was a risk factor and was closely related to clinical indicators. In the multicellular human alveolar model, overexpression of miR-483-5p reduced proliferation and elevated inflammatory factors levels, while inhibition of miR-483-5p increased proliferation and reduced inflammatory factors levels, which is consistent with the trend in the PRAE cell model. MiR-483-5p might participate in PRAE in children by regulating proliferation and inflammatory factors, proving that it may be a biomarker in PRAE. In addition, miR-483-5p was a risk factor for PRAE. In the multicellular human alveolar model, LPS treatment significantly enhanced miR-483-5p expression.